USPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Given the investor's beginner level, long-term strategy, and available funds, USPH is not an immediate buy. Despite strong revenue growth and positive sentiment from dividend increases, the stock's technical indicators suggest a bearish trend with oversold conditions, and the recent drop in net income and EPS raises concerns. Waiting for clearer bullish signals or improved financial performance is advisable.
The stock is currently in a bearish trend. The MACD histogram is negative and expanding, RSI indicates oversold conditions at 13.887, and moving averages are converging. Key support levels are at 76.642 and 72.617, with resistance at 83.157 and 89.672.
Revenue increased by 16.3% YoY in 2025, with record patient visits and strong future guidance.
Quarterly dividend increased by 2.2%, reflecting a commitment to shareholder returns.
Gross margin improved by 7.61% YoY in Q4 2025.
Net income dropped by 47.42% YoY in Q4
EPS declined by 48.08% YoY in Q4
MACD and RSI indicate bearish momentum and oversold conditions.
In Q4 2025, revenue grew by 12.35% YoY to $202.73 million, but net income dropped by 47.42% YoY to $4.15 million. EPS also fell by 48.08% YoY to $0.27. Gross margin improved to 20.65%, up 7.61% YoY.
No data available for analyst ratings or price target changes.
